[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayer Ag ADR (BAYRY)

Bayer Ag ADR (BAYRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 59,677,048
  • Shares Outstanding, K 3,930,000
  • Annual Sales, $ 51,564 M
  • Annual Income, $ -4,096 M
  • EBIT $ 462 M
  • EBITDA $ 3,613 M
  • 60-Month Beta 0.55
  • Price/Sales 1.06
  • Price/Cash Flow 6.35
  • Price/Book 1.61
  • Price/Earnings ttm 9.30
  • Earnings Per Share ttm 1.49
  • Most Recent Earnings $0.79 on 05/12/26
  • Next Earnings Date 08/05/26
  • Annual Dividend & Yield (Fwd) 0.02 (0.17%)
  • Most Recent Dividend 0.024 on 04/28/26
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.23
  • Number of Estimates 2
  • High Estimate $0.26
  • Low Estimate $0.20
  • Prior Year $0.35
  • Growth Rate Est. (year over year) -34.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.8448 +54.24%
on 06/03/26
15.2300 -0.30%
on 07/02/26
+5.3050 (+53.69%)
since 06/02/26
3-Month
9.5840 +58.44%
on 06/02/26
15.2300 -0.30%
on 07/02/26
+3.9250 (+34.86%)
since 04/02/26
52-Week
7.1900 +111.20%
on 08/06/25
15.2300 -0.30%
on 07/02/26
+7.4050 (+95.18%)
since 07/02/25

Most Recent Stories

More News
Luke Bryan and One A Day® Launch Limited Edition Multivitamin Bottles Available Only at Walmart

One A Day®, the multivitamin and supplement brand from Bayer, has partnered with country superstar and five time Entertainer of the Year Luke Bryan to launch a limited edition multivitamin bottle featuring...

BAYRY : 15.1850 (+9.64%)
BAYZF : 60.0000 (+8.62%)
BAYN : 0.0100 (unch)
Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon

Advances key component of Crop Science division’s Five-Year Framework strategy Reinforces commitment to delivering trusted Roundup ® brands and glyphosate...

BAYRY : 15.1850 (+9.64%)
BAYZF : 60.0000 (+8.62%)
BAYN : 0.0100 (unch)
Bayer and Iambic Collaborate to Advance Drug Discovery with AI

Collaboration focuses on small molecule discovery Bayer to leverage Iambic’s AI platform to address hard-to-drug targets Collaboration will strengthen Bayer’s research...

BAYRY : 15.1850 (+9.64%)
BAYZF : 60.0000 (+8.62%)
BAYN : 0.0100 (unch)
Bayer Welcomes Kacy Perry as New Country Division Head for Crop Science Canada

The Crop Science division of Bayer announced that Kacy Perry has been appointed the Country Division Head (CDH) for Crop Science Canada, effective July 1. In this role, she will lead 550+ employees working...

BAYRY : 15.1850 (+9.64%)
BAYZF : 60.0000 (+8.62%)
BAYN : 0.0100 (unch)
Bayer Completes Acquisition of Perfuse Therapeutics

Bayer today announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer. As announced previously ,...

BAYRY : 15.1850 (+9.64%)
BAYZF : 60.0000 (+8.62%)
BAYN : 0.0100 (unch)
Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief

Key Facts Campaign: Project DIY is a new campaign under Aleve’s recently launched Feel Aleve ® platform. Project DIY showcases how, when...

BAYRY : 15.1850 (+9.64%)
BAYZF : 60.0000 (+8.62%)
BAYN : 0.0100 (unch)
Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions

Key Facts: Bayer’s AMBELVIST ® (gadoquatrane) becomes the lowest-dose macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) approved...

BAYRY : 15.1850 (+9.64%)
BAYZF : 60.0000 (+8.62%)
BAYN : 0.0100 (unch)
Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business

Bayer today announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer’s Pharmaceuticals Division, effective August 1, 2026. In his new capacity, he will report...

BAYRY : 15.1850 (+9.64%)
BAYZF : 60.0000 (+8.62%)
BAYN : 0.0100 (unch)
Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth

Bayer today announced leadership changes within its Consumer Health division to accelerate growth, strengthen commercial execution, and further enhance speed of decision making. These changes reflect the...

BAYRY : 15.1850 (+9.64%)
BAYZF : 60.0000 (+8.62%)
BAYN : 0.0100 (unch)
Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease

Investigational results from FIND-CKD provide full efficacy and safety data and is the fifth consecutive Phase III clinical trial where KERENDIA met its primary endpoint—adding to a clinical trial program...

BAYRY : 15.1850 (+9.64%)
BAYZF : 60.0000 (+8.62%)
BAYN : 0.0100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses....

See More

Key Turning Points

3rd Resistance Point 15.5733
2nd Resistance Point 15.4017
1st Resistance Point 15.2933
Last Price 15.1850
1st Support Level 15.0133
2nd Support Level 14.8417
3rd Support Level 14.7333

See More

52-Week High 15.2300
Last Price 15.1850
Fibonacci 61.8% 12.1587
Fibonacci 50% 11.2100
Fibonacci 38.2% 10.2613
52-Week Low 7.1900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.